Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2011-07-19
2011-07-19
Vivlemore, Tracy (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
07982028
ABSTRACT:
The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial.
REFERENCES:
patent: 4880635 (1989-11-01), Janoff et al.
patent: 4906477 (1990-03-01), Kurono et al.
patent: 4911928 (1990-03-01), Wallach
patent: 4917951 (1990-04-01), Wallach
patent: 4920016 (1990-04-01), Allen et al.
patent: 4921757 (1990-05-01), Wheatley et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5885834 (1999-03-01), Epstein
patent: 6025339 (2000-02-01), Nyce et al.
patent: 6165789 (2000-12-01), Monia et al.
patent: 6348450 (2002-02-01), Tang et al.
patent: 7022849 (2006-04-01), Pitts et al.
patent: 2003/0087845 (2003-05-01), Nyce et al.
patent: 2003/0220273 (2003-11-01), Bennett et al.
patent: 2005/0244851 (2005-11-01), Blume et al.
patent: WO97/35989 (1997-10-01), None
patent: WO99/66037 (1999-12-01), None
patent: WO99/67378 (1999-12-01), None
patent: WO00/40714 (2000-11-01), None
patent: WO02/20773 (2002-03-01), None
patent: WO02/22661 (2002-03-01), None
patent: WO03/012030 (2003-02-01), None
patent: WO03/037909 (2003-05-01), None
patent: WO03/064441 (2003-08-01), None
patent: WO2004/016613 (2004-02-01), None
patent: 2004044235 (2004-05-01), None
patent: WO2005/030787 (2005-04-01), None
Essayan, D.M., “Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation”, Biochem. Pharmacol., 1999, 57:965-973.
Perry M.J. et al., “Chemotherapeutic potential of phosphodiesterase inhibitors”, Curr Opin Chem Biol, 1998, 4:472-481.
Bundschuch, D.D. et al., J. Pharmacol. Exp. Ther., 2001, 297:280-290.
Li, L. et al., “CD3- and CD28-dependent induction of PDE7 required for T cell activation”, Science, 1999, 283:848-851.
Burnouf, C. et al., “Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs”, Current Pharmaceutical Design, 2002, 8:1255-1296.
Giembycz, M.A., “Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease”, Expert Opin Invest Drugs, 2001, 10:1361-1379.
Muller et al., TiPS Aug. 1996, 17:294-298.
Szilasi, M. et al., “Pathology of chronic obstructive pulmonary disease”, Pathology Oncology Research, 2006, 12:52-60.
Keatings et al., “Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma”, Am. J. Respir. Crit. Care Med., 1996, 153:530-534.
DeGodoy et al., “Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients”, Am. J. Respir. Crit. Care Med., 1996, 153:633-637.
Torphy, “Phosphodiesterase isozymes: molecular targets for novel antiasthma agents”, Am. J. Respir. Crit. Care Med., 1998, 157:351-370.
Au et al., “Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol”, Br. J. Pharmacol., 1998, 123:1260-1266.
Compton et al., “Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study”, Lancet., 2001, 358:265-270.
Kurreck, J., “Antisense technologies: Improvement through novel chemical modifications”, Eur. J. Biochem., 2003, 270:1628-1644.
Wilds, C.J. et al., “2′-Deoxy-2′-fluoro-b-D-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physiochemical studies”, Nucl. Acids Res., 2000, 28:3625-3635.
Ma et al. Mol. Pharmacol., 1999, 55, 50-57.
Wang et al., Molec. Pharmocol., 1999, 56:170-174.
Churg et al., Am J Respir Crit. Care Med., 2000, 166:849-854.
Churg, et al. AM J Respir Crit. Mol. Biol., 2002, 27:368-374.
Gaede, K.I. et al. (1999) J. Mol. Med. 77:847-852.
Kebelmann-Betzing, C. et al. (2001) Cytokine. 13:39-50.
Ishii, Y et al. (2003) Int. J. Cancer. 103:161-168.
Weintraub et al., Scientific American, Jan. 1990: 40-46.
Nemoz et al., FEBS Letters 1996, 384:97-102.
Wang et al., Biochemical and Biophysical Research Communications 2000, 276:1271-1277.
MacKenzie et al., Proc. Natl. Acad. Sci. USA, Mar. 1999, vol. 95, No. 7, pp. 3549-3554.
Soderling et al., Curr. Opin. Cell. Bio., Apr. 2000, vol. 12, No. 2, pp. 174-179.
Epstein, Methods: A companion to methods in enzymology. Jan. 1998, vol. 14, No. 1, pp. 21-33.
Clayton et al., Respiratory Research, 2004, 5.
McCluskie et al., American Society for Pharmacology and Experimental Therapeutics, JPET #105080, 2006.
Smith et al., Molecular Pharmacology 2004, vol. 66, No. 6, 1679.
Robichaud et al., J. Clinical Investigation 2002, 110 (7) : 1045.
Robichaud et al., Brit. J. Pharmacology 2002, 135: 113.
Calverley et al., Am. J. Respir. Cult. Care. Med. 2007, 176:154.
Dietsch et al., Toxicologic Phatology 2006, 34:39.
Supplementary European Search Report dated Jul. 20, 2010 from European Patent Application No. 07719824.
Chung, F.F. et al. “Phosphodiesterase inhibitors in airways disease”, European Journal of Pharmacology, 2006, 533:110-117.
Fortin, M. et al., “A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice”, Respiratory Research, 2009, 10:39.
D'Anjou Helene
Paquet Luc
Renzi Paolo
Pepper Hamilton LLP
Topigen Pharmaceuticals, Inc.
Vivlemore Tracy
LandOfFree
Oligonucleotides affecting expression of phosphodiesterases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotides affecting expression of phosphodiesterases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotides affecting expression of phosphodiesterases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2638454